UBS analyst Esther Rajavelu reiterated a Neutral rating and $45.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented, “We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE